source
- GSK licenses Hutchmed's KRAS-EGFR antibody-drug conjugate for $110 million upfrontGSK announced it will pay $110 million upfront to obtain a license for a KRAS-EGFR antibody-drug conjugate developed by Chinese biopharma Hutchmed. The agreement also includes potential milestone p…
- Merck's dealmaker warns of increased M&A activity as Keytruda patent expiresMerck's chief M&A officer says the company expects a surge in deal flow as the patent for its flagship immunotherapy, Keytruda, approaches expiration. The leadership has been pursuing acquisitions…